There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), AbbVie (ABBV – Research Report) and Establishment Labs Holdings (ESTA – Research Report) with bullish sentiments.
Regeneron (REGN)
BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron today and set a price target of $1025.00. The company’s shares closed last Wednesday at $696.88.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $844.00, which is a 20.8% upside from current levels. In a report issued on January 9, Piper Sandler also maintained a Buy rating on the stock with a $765.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
AbbVie (ABBV)
In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on AbbVie, with a price target of $169.00. The company’s shares closed last Wednesday at $156.23.
According to TipRanks.com, Nachman is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $159.29 average price target, implying a -0.2% downside from current levels. In a report issued on January 5, Truist Financial also maintained a Buy rating on the stock with a $180.00 price target.
Establishment Labs Holdings (ESTA)
In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Establishment Labs Holdings, with a price target of $100.00. The company’s shares closed last Wednesday at $61.75.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of
Establishment Labs Holdings has an analyst consensus of Strong Buy, with a price target consensus of $86.75, implying a 40.1% upside from current levels. In a report issued on December 28, Stephens also maintained a Buy rating on the stock with a $87.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Piper ‘at a loss’ to explain Regeneron Q4 miss for Eylea
- Regeneron sees about $1.5B in Q4 U.S. net product sales of Eylea
- FDA Dermatologic & Ophthalmic Drugs Advisory Committee Virtual Meeting
- 2seventy Bio announces amendment to collaboration with Regeneron
- CytomX Therapeutics updates business, announces 2023 relationship with Moderna
